TRDA
NASDAQEntrada Therapeutics Inc.
Price$6.45-7.06 (-52.29%)
2026-03-112026-06-12
News · 26 weeks40-10%
2025-12-212026-06-14
Mix2390d
- Insider10(43%)
- SEC Filings6(26%)
- Earnings3(13%)
- Analyst2(9%)
- Other2(9%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Parmar Kush4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERSEC Form 4 filed by Director Kim Peter S4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERSEC Form 4 filed by Director Chapman Gina4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERSEC Form 4 filed by Director Radhakrishnan Maha4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERSEC Form 4 filed by Director Thistle Mary4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERSEC Form 4 filed by Director Zeiher Bernhardt G4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SECEntrada Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
- PRIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study-- Participants in Cohort 1 have progressed to the open-label, Phase 2 portion of ELEVATE-45-201 -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026 -- BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-45-201. The DMC recommended initiation of the Cohort 2 dose at 10 mg/kg, a dose escalation from 5 mg/kg in Cohort 1. ELEVATE-45-201 is a Phase 1/2 MAD clinical study
- PREntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today announced that the Company granted an aggregate of 18,600 restricted stock units ("RSUs") to three newly-hired non-executive employees under the Company's 2025 Inducement Equity Plan (the "Inducement Plan"), effective as of June 1, 2026. The inducement grants were previously approved by the Compensation Committee of the Company's Board of Directors, as a material inducement to the new employees' entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). One-fourth of the RSUs will vest on the one-year anniversary of the vesting commencement date, and 6.25% shall vest qua
- INSIDERDirector Zeiher Bernhardt G bought $29,316 worth of shares (5,000 units at $5.86) (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- ANALYSTEntrada Therapeutics downgraded by H.C. WainwrightH.C. Wainwright downgraded Entrada Therapeutics from Buy to Neutral
- SECSEC Form 10-Q filed by Entrada Therapeutics Inc.10-Q - Entrada Therapeutics, Inc. (0001689375) (Filer)
- SECEntrada Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Entrada Therapeutics, Inc. (0001689375) (Filer)
- PREntrada Therapeutics Reports First Quarter 2026 Financial Results-- Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early functional benefit -- -- Company on track to report ELEVATE-45-201 Cohort 1 data in mid-2026, as well as ELEVATE-44-201 open-label period and Cohort 2 data by year-end 2026 -- -- Cash runway expected into Q3 2027 with $255 million in cash, cash equivalents and marketable securities as of March 31, 2026 -- -- Entrada to host investor webcast and conference call today, Thursday, May 7, at 8:30 a.m. ET -- BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) today reported financial results for the first quarter ended Ma
- PREntrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study-- Achieved the primary objective with favorable safety and tolerability, no discontinuations and no serious adverse events -- -- Markers of kidney function via eGFR, Cystatin C and magnesium were all within normal ranges and comparable to placebo -- -- Observed lower plasma exposure in Cohort 1 participants who are all between six and 17 years of age when compared with healthy adult volunteers; A similar trend was seen between recently received juvenile and adult NHP PK data -- -- Consequently, Cohort 1 demonstrated an increase of 2.36% in dystrophin over a baseline of 4.00% and an increase of 2.31% in exon skipping over a baseline of 2.66% in treated participants -- -- Statistically s
- PREntrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (NASDAQ:TRDA) will announce topline results from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 on Thursday, May 7, 2026. The Company will host an investor webcast and conference call at 8:30 a.m. ET to discuss these clinical results. The webcast can be accessed by visiting the Investor Relations section of the Company's website at www.entradatx.com. Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here. The webcast will be archived and availab
- INSIDERPresident, Research & Develop. Sethuraman Natarajan sold $398,810 worth of shares (25,907 units at $15.39) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 216,317 units (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERPresident & COO Dowden Nathan J exercised 15,000 shares at a strike of $1.74 and sold $229,953 worth of shares (15,000 units at $15.33) as part of a pre-agreed trading plan (SEC Form 4)4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- SECSEC Form DEFA14A filed by Entrada Therapeutics Inc.DEFA14A - Entrada Therapeutics, Inc. (0001689375) (Filer)
- SECSEC Form DEFA14A filed by Entrada Therapeutics Inc.DEFA14A - Entrada Therapeutics, Inc. (0001689375) (Filer)
- SECSEC Form DEF 14A filed by Entrada Therapeutics Inc.DEF 14A - Entrada Therapeutics, Inc. (0001689375) (Filer)
- INSIDERSEC Form 4 filed by Wentworth Kory James4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- ANALYSTCantor Fitzgerald initiated coverage on Entrada TherapeuticsCantor Fitzgerald initiated coverage of Entrada Therapeutics with a rating of Overweight
- INSIDERSEC Form 4 filed by Entrada Therapeutics Inc.4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
- INSIDERSEC Form 4 filed by Entrada Therapeutics Inc.4 - Entrada Therapeutics, Inc. (0001689375) (Issuer)
TRDA FAQ
7 questionsWhat does Entrada Therapeutics Inc. do?
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy. It also engages in the development of EEV-PMO for the treatment of Duchenne myotonic dystrophy type 1 (DM1). The company was formerly known as CycloPorters, Inc. and changed its name to...Where does TRDA stock trade?
Entrada Therapeutics Inc. (TRDA) is listed on NASDAQ.What sector and industry is TRDA in?
Entrada Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Entrada Therapeutics Inc. go public?
Entrada Therapeutics Inc. (TRDA) completed its IPO in 2021.What are analysts saying about TRDA?
Entrada Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2026-05-08. Recent price targets range from $2000.00 to $2900.00.What companies are similar to TRDA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TRDA side-by-side with any of them on Quantisnow.How can I track TRDA on Quantisnow?
Quantisnow aggregates Entrada Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TRDA to receive live email and push alerts on every new disclosure.